A RIPK1-specific PROTAC degrader achieves potent antitumour activity by enhancing immunogenic cell death.  Mannion et al.

Name: A RIPK1-specific PROTAC degrader achieves potent antitumour activity by enhancing immunogenic cell death. Mannion et al.
Creator: Jonathan Mannion
Published: 2024-05-24T20:17:48.946Z
Keywords: Molecular Biology, Radiation, Cancer, Innate Immunity, Immune Checkpoint Inhibitor, Immunogenic Cell Death

Mannion, Jonathan; Gifford, Valentina; Bellenie, Benjamin; Fernando, Winnie; Ramos Garcia, Laura; Wilson, Rebecca; Wicky John, Sidonie; Udainiya, Savita; Patin, Emmanuel; Tiu, Crescens; Smith, Angel; Goicoechea, Maria; Craxton, Andrew; Moraes de Vasconcelos, Nathalia; Guppy, Naomi; J Cheung, Kwai-Ming; J. Cundy, Nicholas; Pierrat, Olivier; Brennan, Alfie; I. Roumeliotis, Theodoros; Bensead-Hume, Graeme; Alexander, John; Muirhead, Gareth; Layzell, Scott; Lyu, Wenxin; Roulstone, Victoria; Allen, Mark; Balldock, Holly; Legrand, Arnaud; Gabel, Florian; Serrano-Aparicio, Natalia; Starling, Chris; Guo, Hongyan; Upton, Jason; Gyrd-Hansen, Mads; MacFarlane, Marion; Seddon, Benedict; Raynaud, Florence; Roxanis, Ioannis; Harrington, Kevin; Haider, Syed; S. Choudhary, Jyoti; Hoelder, Swen; Tenev, Tencho; Meier, Pascal

doi:10.17632/822syk52yw.1

A RIPK1-specific PROTAC degrader achieves potent antitumour activity by enhancing immunogenic cell death. Mannion et al.

Published: 24 May 2024| Version 1 | DOI: 10.17632/822syk52yw.1

Contributors:

,

, Laura Ramos Garcia,

,

, Alfie Brennan,

,

, John Alexander,

,

, Wenxin Lyu,

,

Description

Original data from the images and western blots from the paper: A RIPK1-specific PROTAC degrader achieves potent antitumour activity by enhancing immunogenic cell death.

Files

Institutions

Institute of Cancer Research

Funding

Breast Cancer Now

Cancer Research UK

A RIPK1-specific PROTAC degrader achieves potent antitumour activity by enhancing immunogenic cell death. Mannion et al.

Description

Files

Institutions

Categories

Funding

Licence